On Friday, Esperion Therapeutics Inc (NASDAQ: ESPR) opened lower -4.03% from the last session, before settling in for the closing price of $1.24. Price fluctuations for ESPR have ranged from $0.69 to $3.94 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 40.11% over the past five years. Company’s average yearly earnings per share was noted 45.54% at the time writing. With a float of $194.62 million, this company’s outstanding shares have now reached $196.66 million.
Let’s look at the performance matrix of the company that is accounted for 304 employees. In terms of profitability, gross margin is 65.3%, operating margin of -15.4%, and the pretax margin is -59.03%.
Esperion Therapeutics Inc (ESPR) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Esperion Therapeutics Inc is 1.80%, while institutional ownership is 57.48%. The most recent insider transaction that took place on Jun 17 ’25, was worth 7,398. In this transaction General Counsel of this company sold 6,422 shares at a rate of $1.15, taking the stock ownership to the 401,241 shares. Before that another transaction happened on Jun 17 ’25, when Company’s President and CEO sold 30,474 for $1.11, making the entire transaction worth $33,796. This insider now owns 1,541,488 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 45.54% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Check out the current performance indicators for Esperion Therapeutics Inc (ESPR). In the past quarter, the stock posted a quick ratio of 0.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ: ESPR) saw its 5-day average volume 3.52 million, a negative change from its year-to-date volume of 4.63 million. As of the previous 9 days, the stock’s Stochastic %D was 87.14%.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 40.20%, which indicates a significant decrease from 77.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0812 in the past 14 days, which was lower than the 0.0930 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0084, while its 200-day Moving Average is $1.7053. Nevertheless, the first resistance level for the watch stands at $1.2300 in the near term. At $1.2700, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3000. If the price goes on to break the first support level at $1.1600, it is likely to go to the next support level at $1.1300. Assuming the price breaks the second support level, the third support level stands at $1.0900.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are currently 198,199K shares outstanding in the company with a market cap of 235.86 million. Presently, the company’s annual sales total 332,310 K according to its annual income of -51,750 K. Last quarter, the company’s sales amounted to 65,000 K and its income totaled -40,460 K.
